tetano
Editor, Senior Moderator
T Cell Transcriptional Signatures of Influenza A/H3N2 Antibody Response to High Dose Influenza and Adjuvanted Influenza Vaccine in Older Adults
Iana H Haralambieva[SUP] 1 [/SUP], Huy Quang Quach[SUP] 1 [/SUP], Inna G Ovsyannikova[SUP] 1 [/SUP], Krista M Goergen[SUP] 2 [/SUP], Diane E Grill[SUP] 2 [/SUP], Gregory A Poland[SUP] 1 [/SUP], Richard B Kennedy[SUP] 1 [/SUP]
Affiliations
Abstract
Older adults experience declining influenza vaccine-induced immunity and are at higher risk of influenza and its complications. For this reason, high dose (e.g., Fluzone) and adjuvanted (e.g., Fluad) vaccines are preferentially recommended for people age 65 years and older. However, T cell transcriptional activity shaping the humoral immune responses to Fluzone and Fluad vaccines in older adults is still poorly understood. We designed a study of 234 older adults (≥65 years old) who were randomly allocated to receive Fluzone or Fluad vaccine and provided blood samples at baseline and at Day 28 after immunization. We measured the humoral immune responses (hemagglutination inhibition/HAI antibody titer) to influenza A/H3N2 and performed mRNA-Seq transcriptional profiling in purified CD4[SUP]+[/SUP] T cells, in order to identify T cell signatures that might explain differences in humoral immune response by vaccine type. Given the large differences in formulation (higher antigen dose vs adjuvant), our hypothesis was that each vaccine elicited a distinct transcriptomic response after vaccination. Thus, the main focus of our study was to identify the differential gene expression influencing the antibody titer in the two vaccine groups. Our analyses identified three differentially expressed, functionally linked genes/proteins in CD4[SUP]+[/SUP] T cells: the calcium/calmodulin dependent serine/threonine kinase IV (CaMKIV); its regulator the TMEM38B/transmembrane protein 38B, involved in maintenance of intracellular Ca2[SUP]+[/SUP] release; and the transcriptional coactivator CBP/CREB binding protein, as regulators of transcriptional activity/function in CD4[SUP]+[/SUP] T cells that impact differences in immune response by vaccine type. Significantly enriched T cell-specific pathways/biological processes were also identified that point to the importance of genes/proteins involved in Th1/Th2 cell differentiation, IL-17 signaling, calcium signaling, Notch signaling, MAPK signaling, and regulation of TRP cation Ca2[SUP]+[/SUP] channels in humoral immunity after influenza vaccination. In summary, we identified the genes/proteins and pathways essential for cell activation and function in CD4[SUP]+[/SUP] T cells that are associated with differences in influenza vaccine-induced humoral immunity by vaccine type. These findings provide an additional mechanistic perspective for achieving protective immunity in older adults.
Keywords: T cells; gene expression profiling; genetic markers; hemagglutination inhibition; humoral; immunity; influenza; influenza vaccine; transcriptome.
Iana H Haralambieva[SUP] 1 [/SUP], Huy Quang Quach[SUP] 1 [/SUP], Inna G Ovsyannikova[SUP] 1 [/SUP], Krista M Goergen[SUP] 2 [/SUP], Diane E Grill[SUP] 2 [/SUP], Gregory A Poland[SUP] 1 [/SUP], Richard B Kennedy[SUP] 1 [/SUP]
Affiliations
- PMID: 36560767
- DOI: 10.3390/v14122763
Abstract
Older adults experience declining influenza vaccine-induced immunity and are at higher risk of influenza and its complications. For this reason, high dose (e.g., Fluzone) and adjuvanted (e.g., Fluad) vaccines are preferentially recommended for people age 65 years and older. However, T cell transcriptional activity shaping the humoral immune responses to Fluzone and Fluad vaccines in older adults is still poorly understood. We designed a study of 234 older adults (≥65 years old) who were randomly allocated to receive Fluzone or Fluad vaccine and provided blood samples at baseline and at Day 28 after immunization. We measured the humoral immune responses (hemagglutination inhibition/HAI antibody titer) to influenza A/H3N2 and performed mRNA-Seq transcriptional profiling in purified CD4[SUP]+[/SUP] T cells, in order to identify T cell signatures that might explain differences in humoral immune response by vaccine type. Given the large differences in formulation (higher antigen dose vs adjuvant), our hypothesis was that each vaccine elicited a distinct transcriptomic response after vaccination. Thus, the main focus of our study was to identify the differential gene expression influencing the antibody titer in the two vaccine groups. Our analyses identified three differentially expressed, functionally linked genes/proteins in CD4[SUP]+[/SUP] T cells: the calcium/calmodulin dependent serine/threonine kinase IV (CaMKIV); its regulator the TMEM38B/transmembrane protein 38B, involved in maintenance of intracellular Ca2[SUP]+[/SUP] release; and the transcriptional coactivator CBP/CREB binding protein, as regulators of transcriptional activity/function in CD4[SUP]+[/SUP] T cells that impact differences in immune response by vaccine type. Significantly enriched T cell-specific pathways/biological processes were also identified that point to the importance of genes/proteins involved in Th1/Th2 cell differentiation, IL-17 signaling, calcium signaling, Notch signaling, MAPK signaling, and regulation of TRP cation Ca2[SUP]+[/SUP] channels in humoral immunity after influenza vaccination. In summary, we identified the genes/proteins and pathways essential for cell activation and function in CD4[SUP]+[/SUP] T cells that are associated with differences in influenza vaccine-induced humoral immunity by vaccine type. These findings provide an additional mechanistic perspective for achieving protective immunity in older adults.
Keywords: T cells; gene expression profiling; genetic markers; hemagglutination inhibition; humoral; immunity; influenza; influenza vaccine; transcriptome.